All In Biotech

Drug Trial Radar · NCT06087003

Pediatric Induction Therapy in Kidney Transplantation

Induction Therapy of Thymoglobulin Versus Basiliximab in the Prevention of Acute Rejection After Pediatric Kidney Transplantation

Last checked: Nov 20, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

958

Actual

Start

Mar 3, 2013

Primary completion

Jul 27, 2022

Study completion Sep 30, 2023

Sponsor

Lead sponsor
Gang ChenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zhejiang University; First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital of Zhengzhou University; Changhai Hospital
First posted
Oct 17, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is: Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy? The transplant and follow-up data of participants will be retrospectively collected. Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.

Conditions

  • Kidney Transplant Rejection
  • Pediatric Kidney Disease

Interventions

  • Basiliximab InjectionDrug

    As an induction treatment for kidney transplantation

  • rabbit ATGDrug

    As an induction treatment for kidney transplantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute rejection (AR)Time frame: From baseline, kidney transplantation to data collection completion (June 30, 2023)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Zhejiang University

    Hangzhou, China

  • Changhai Hospital affiliated to Naval Military Medical University

    Shanghai, China

  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, China

  • The First Affiliated Hospital of Sun Yat-sen University.

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.